Somewhat Positive Media Coverage Somewhat Unlikely to Affect Apollo Endosurgery (APEN) Stock Price
Media coverage about Apollo Endosurgery (NASDAQ:APEN) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Apollo Endosurgery earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.6378628480012 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- Northland Securities Reaffirms “Buy” Rating for Apollo Endosurgery (APEN) (americanbankingnews.com)
- Apollo Endosurgery (APEN) Announces FDA Clearance for OverStitch Sx Endoscopic Suturing System (streetinsider.com)
- Apollo Endosurgery’s stock rockets on FDA clearance of OverStitch Sx (marketwatch.com)
- Apollo Endosurgery Surges on FDA Approval (247wallst.com)
- Apollo Endosurgery Inc. (APEN) Is Surging After Receiving FDA Clearance (rttnews.com)
Several research analysts have recently weighed in on APEN shares. Northland Securities started coverage on Apollo Endosurgery in a research report on Tuesday, September 26th. They issued an “outperform” rating and a $12.00 price objective for the company. Zacks Investment Research raised Apollo Endosurgery from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Thursday, November 2nd. ValuEngine lowered Apollo Endosurgery from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 3rd. Finally, Roth Capital started coverage on Apollo Endosurgery in a research report on Wednesday, August 2nd. They issued a “buy” rating and a $10.00 price objective for the company. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $9.44.
Shares of Apollo Endosurgery (NASDAQ APEN) opened at $4.70 on Thursday. Apollo Endosurgery has a 12-month low of $3.55 and a 12-month high of $21.88. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.54 and a quick ratio of 2.00.
In other news, VP Bret Schwartzhoff bought 9,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 7th. The stock was acquired at an average cost of $4.24 per share, with a total value of $40,280.00. Following the transaction, the vice president now directly owns 15,631 shares of the company’s stock, valued at approximately $66,275.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 74.20% of the company’s stock.
Apollo Endosurgery Company Profile
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.